Catalyst Pharmaceuticals Ownership
| CPRX Stock | USD 21.19 0.29 1.35% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 125 M | Current Value 125 M | Avarage Shares Outstanding 74.6 M | Quarterly Volatility 37.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Catalyst |
Catalyst Stock Ownership Analysis
About 82.0% of the company shares are held by institutions such as insurance companies. The book value of Catalyst Pharmaceuticals was currently reported as 5.54. The company had not issued any dividends in recent years. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. For more info on Catalyst Pharmaceuticals please contact Richard MBA at 305 420 3200 or go to https://www.catalystpharma.com.Besides selling stocks to institutional investors, Catalyst Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Catalyst Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Catalyst Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Catalyst Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Catalyst Pharmaceuticals Insider Trades History
About 6.0% of Catalyst Pharmaceuticals are currently held by insiders. Unlike Catalyst Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Catalyst Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Catalyst Pharmaceuticals' insider trades
Catalyst Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Catalyst Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Catalyst Pharmaceuticals backward and forwards among themselves. Catalyst Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Catalyst Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royce & Associates, Lp | 2024-09-30 | 2 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Boston Partners Global Investors, Inc | 2024-09-30 | 1.3 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.2 M | Goldman Sachs Group Inc | 2024-06-30 | 1.1 M | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.1 M | Kennedy Capital Management Inc | 2024-09-30 | 1 M | Blackrock Inc | 2024-06-30 | 18.7 M | Vanguard Group Inc | 2024-09-30 | 8 M |
Catalyst Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Catalyst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Catalyst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Catalyst Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Catalyst Pharmaceuticals Outstanding Bonds
Catalyst Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Catalyst Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Catalyst bonds can be classified according to their maturity, which is the date when Catalyst Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Catalyst Pharmaceuticals Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 6th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 26th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.